SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Business
One Busy Week for AbbVie: Hepatitis C, Fibroids, Alzheimer’s & Parkinson’s, and Generic Criticism
AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to?
November 15, 2018
 · 
4 min read
 · 
Mark Terry
Business
AbbVie’s Mavyret Demonstrates Sky-High Cure Rates in Hepatitis C
Chicago-based AbbVie just announced new data for its Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.
November 14, 2018
 · 
3 min read
 · 
Mark Terry
BioMidwest
Updated: Amgen Co-Founds Fund to Help Conejo Valley Shooting Victims; Donates to Wildfire Victims
The fund will be administered through the Ventura County Community Foundation. Officials indicate that 100 percent of the funds will go to help victims’ families. The Foundation is calling for additional donations.
November 8, 2018
 · 
3 min read
 · 
Mark Terry
Genetown
15 Massachusetts Life Science Companies That Spend the Most on R&D
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
November 8, 2018
 · 
4 min read
 · 
Mark Terry
Business
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million
Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.
November 7, 2018
 · 
3 min read
 · 
Mark Terry
Why Bristol-Myers' Future is Highly Dependent on T
FDA
BMS’ Empliciti Garners a New FDA Indication for Multiple Myeloma
Joseph Eid, head of medical at BMS, said Empliciti in combination with pomalidomide and dexamethasone has provided proof that the medication can extend the time a patient can live without the worsening of his or her disease.
November 7, 2018
 · 
3 min read
 · 
Alex Keown
Business
AbbVie Follows Trend of Big Pharma Setting Office-Labs in Biotech Clusters
In what appears to be a trend, big pharma company AbbVie is leasing 479,000 square feet of space inBioMed Realty’s Gateway of Pacific project in South San Francisco.
November 2, 2018
 · 
3 min read
 · 
Mark Terry
Business
Early November Brings More Quarterly Reports
Biopharma companies set to release financial reports next week have reported positive news in recent months.
November 1, 2018
 · 
3 min read
 · 
Alex Keown
Business
Roche and AbbVie Push Towards First-Line CLL Treatment
A study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.
November 1, 2018
 · 
3 min read
 · 
Mark Terry
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Genetown
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
June 5, 2020
 · 
4 min read
Drug Development
New Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
June 4, 2020
 · 
21 min read
BioMidwest
AbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference
June 3, 2020
 · 
2 min read
BioMidwest
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
June 1, 2020
 · 
16 min read
Business
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
June 1, 2020
 · 
3 min read
FDA
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
May 29, 2020
 · 
13 min read
BioMidwest
AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
May 27, 2020
 · 
19 min read
BioMidwest
AbbVie Announces 26 Nonprofits Selected for the COVID-19 Community Resilience Fund
May 21, 2020
 · 
10 min read
Business
Synlogic Announces Termination of AbbVie Collaboration Agreement
May 21, 2020
 · 
4 min read
BioMidwest
AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio
May 15, 2020
 · 
31 min read
Load More